INTRA-CELLULAR THERAPIES REPORTS FOURTH QUARTER AND FULL-YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Full year 2023 total revenues of $464.4 million, compared to$250.3 million in 2022 Full year 2023 CAPLYTA net product sales were $462.2 million, representing year-over-year growth of 86$131.5 million, a 50% increase over the same period in 2022 Exhibit 99.1 In 2023, CAPLYTA total prescriptions achieved strong year-over-year growth of 85% ...